Featured in this issue are an ensemble of papers exploring aspects of second-generation sequencing, a technology space that continues to undergo breathtakingly rapid development.
A variety of high-throughput sequencing platforms have matured sufficiently to have been used to tackle significant biological problems. While the technologies differ in many details, they have a number of common features. Whereas the previous generation of Sanger sequencing segregated individual samples into lanes or capillaries and separated bases in space, the new generation rely on DNA molecules (or amplified clonal clusters of DNA molecules) arrayed on a two-dimensional space, with bases being resolved in time.
Perhaps the most important distinction versus the older technology was a gross inferiority on almost every performance dimension: much shorter reads and much higher error rates with slower sequencing runs and at a higher cost per run. Only on two dimensions did the newcomers hold any advantage: the cost per fragment sequenced and cost per nucleotide read. Hence, the new generation of sequencers were textbook examples of disruptive technology. As with other such technologies, most initial uses were in applications ill-served by the mature Sanger technology, or at least in areas (such as ancient DNA sequencing) in which the advantages of the older technology were blunted.
Both the short reads and low quality of the new sequencing data made them a poor fit for the bioinformatic tools optimized for the old regime. Furthermore, the volume of data generated was many orders of magnitude greater. In addition, entirely new applications were developed for these machines. So a frenzied era of bioinformatic tool development began, an era which has probably not peaked and certainly not ended.
Our offerings in this issue span a range of topics in this space, though against the variety of applications to which these technologies have been applied our set is necessarily incomplete. However, what we do have to offer can be grouped into two broad categories.
First is the general question of exploring genomes using the new technology. Such explorations fall naturally into two categories: exploring entirely new genomes and further expeditions into known genomes. In the first category, Paszkiewicz and Studholme describe the challenges and approaches used for the de novo of assembly of genomes from second-generation data, which has even now been attempted for a complex mammalian genome (giant panda). On the other side, Li and Homer review the challenges faced in aligning short reads to reference genomes for resequencing projects. Koboldt and colleagues review the very practical issues faced when resequencing many human genomes in a high-throughput setting. A running theme through all of these is the challenge with coping with the immense volumes of data generated and which, even with clever and efficient algorithms, impose striking requirements for compute power, memory and permanent storage.
The other half of our section focuses on exploring specific types of biological questions with these magnificent machines. Werner surveys the broad range of functional studies that have been enabled by second-generation sequencing. Huss focuses the many approaches to elucidating epigenetic information, an area in which these technologies found an early footing because neither read length nor precise quality were as important as simply volumes of tags. Finally, my own contribution covers the application of second-generation sequencing to enumerating mutations and structural variations in cancer genomes.
The rapid pace of ongoing development in these areas could serve as a deterrent to even attempting a review. Indeed, several of the reviews incorporate material published only weeks prior to the manuscripts' submission, and probably any one of them could have been augmented by half a dozen papers published in the brief interval between submission and acceptance. However, I would argue the opposite position that it is this rapid development, which makes collections such as these particularly valuable, by providing a benchmark for further discussion and a snapshot of a particular time in the development of the field.
Happily, there is truly no end in sight. Enormous investments in the field have been driven by visions of whole genome sequencing integrated into routine medical practice. New technology platforms promise new capabilities, and the re-packing and evolution of older platforms promise even greater accessibility to scientists. The data deluge only grows, and tantalizing hints of new disruptive changes have emerged. For example, read lengths well in excess of Sanger sequencing may soon be widely available, as well as long-range physical maps in the form of series of many sequencing reads from the same DNA molecule with known separation. Undoubtedly these new features will require new tools to utilize them, even if avenues to wring more information from the existing technologies continue to be explored. Advanced sequencing technologies will continue to be a fruitful field of bioinformatics endeavour both in supporting the technologies directly as well as enabling entirely new methods of biological discovery.
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